• MeSH
• interleukin-2 * analýza   fyziologie   terapeutické užití   MeSH
• lidé MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• interleukin-2 * MeSH

During the last several years, the important progress has been achieved in studying activation and proliferation processes altogether with differentiation of mononuclear cells and regulatory course of immune response. In addition to molecular biology, also the biochemical characterization of interleukins, mainly Interleukin 2 (IL 2), is of a substantial import. IL 2 is actionning as an amplificator of T and B immune cellular reactions, and it influences the production of lymphokines, i.e., gamma interferon as well as participates in antitumorous immunity. IL 2 belongs to the range of products being secreted by T lymphocytes following the specific antigenic or polyclonal mitogenic simulation of cells. It can be classed as a growth factor of cells and regulatory factor of immune responsiveness. The human IL 2 was isolated as a protein with Mr 16 kD. On the basis of complementary DNA, the molecular weight has been determined for IL 2 as 15.4 kD. The IL 2-related human gen is localized on 4th chromosome and the product of the respective gen is a protein composed of 133 amino acids. This very protein undergoes glycosylation on the 3d position having alpha-helicoid conformation. The murine IL 2 occurs rather as a dimer composed of two protein chains with Mr 16-18 kD. Variable degrees of glycosylation involve the heterogeneity and pI differences in isolated forms of IL 2. Actions of IL2 are triggered by its interaction with specific receptor, which appears on the T cells no sooner as they are activated by the antigen or mitogen. Following the IL 2 with receptor interaction, the hydrolysis of phosphatidylinositolphosphate occurs intracellularly as well as activation of proteinkinase C and a track of other biochemical reactions non-elucidated till now, which lead up to the transcription regulation of genes and transfer of mitotic apparatus from G1 into S phase of cellular cycle and of division of cells.

• MeSH
• chemické jevy MeSH
• chemie MeSH
• interleukin-2 * metabolismus   fyziologie   MeSH
• lidé MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• interleukin-2 * MeSH

The effect of isoniazid on interleukin 2 production and interleukin 2-receptor expression by phytohemagglutinin-stimulated human T cells was investigated. High concentrations of the drug decreased interleukin 2 production while low doses (10(-5)-10(-6) M) produced a slight increase in interleukin 2 production. Isoniazid did not affect the expression of interleukin 2-receptors on the surface of T cells, except a slight decrease in cells exposed to high levels of the drug.

• MeSH
• buněčné dělení účinky léků   MeSH
• interleukin-2 biosyntéza   MeSH
• isoniazid farmakologie   MeSH
• kultivované buňky MeSH
• lidé MeSH
• receptory interleukinu-2 účinky léků   MeSH
• T-lymfocyty účinky léků   metabolismus   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• interleukin-2 MeSH
• isoniazid MeSH
• receptory interleukinu-2 MeSH

Transplantation tolerance was induced in mice by inoculating newborn animals with semi-allogeneic haematopoietic cells. The mice rendered tolerant were treated within the first week of birth, or at the time of grafting (age 7-8 weeks), with recombinant interleukin-1 (rIL-1) or interleukin-2 (rIL-2). The effects of these treatments on tolerance induction were monitored in terms of skin allograft survival. Treatment of newborn mice with rIL-2 abolished tolerance induction in nearly all tested animals. When administered at the time of grafting, both rIL-1 and rIL-2 decreased the proportion of tolerant animals. However, these modulation effects of interleukins were only observed in strain combinations with genetic differences at the K end of H-2 or in the entire H-2 complex, in which it is difficult to establish permanent tolerance; no effects of interleukins on tolerance induction were found in a strain combination with a relatively weaker genetic barrier represented by incompatibility at the D region of the H-2 complex.

• MeSH
• H-2 antigeny genetika   MeSH
• homologní transplantace MeSH
• imunologická tolerance * MeSH
• inbrední kmeny myší MeSH
• interleukin-1 farmakologie   MeSH
• interleukin-2 farmakologie   MeSH
• myši MeSH
• slezina transplantace   MeSH
• transplantace kostní dřeně MeSH
• transplantace kůže MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• H-2 antigeny MeSH
• interleukin-1 MeSH
• interleukin-2 MeSH

The production of interleukin-2 (IL-2) by phytohemaglutinin (PHA)-stimulated cells of human leukemia T cell line MOLT-16 can be significantly increased by interleukin-1 (IL-1) or interferon-alpha (IFN-alpha). The enhancing effect of IL-1 and IFN-alpha on IL-2 production was studied at the IL-2 mRNA level. We show that IL-1 enhances considerably and transiently, with the maximum level between 1 and 2 hr after stimulation, the expression of IL-2 mRNA in the PHA-stimulated cells. The level of IL-2 mRNA declined rapidly within 4 to 6 hr after stimulation in both PHA- and PHA plus IL-1-stimulated cell cultures. On the contrary, IFN-alpha does not elevate the level of IL-2 mRNA above the level in PHA-stimulated cultures, but maintains an enhanced level of IL-2 mRNA in the activated cells for more than 6 hr after stimulation. These observations correlate well with the kinetics of IL-2 protein production into the culture media. The results thus suggest that IL-1 and IFN-alpha may exert an enhancing effect on IL-2 production by distinct mechanisms. In addition, none of the five other lymphokines tested (i.e., IL-2, IL-3, IL-4, IL-5, and IL-6) had any significant effect on IL-2 mRNA expression in the activated MOLT-16 cells.

• MeSH
• aktivace lymfocytů MeSH
• buněčné linie MeSH
• časové faktory MeSH
• exprese genu účinky léků   MeSH
• interferon alfa farmakologie   MeSH
• interleukin-1 farmakologie   MeSH
• interleukin-2 genetika   farmakologie   MeSH
• interleukin-3 farmakologie   MeSH
• interleukin-4 farmakologie   MeSH
• interleukin-5 farmakologie   MeSH
• interleukin-6 farmakologie   MeSH
• lidé MeSH
• messenger RNA genetika   MeSH
• techniky in vitro MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• interferon alfa MeSH
• interleukin-1 MeSH
• interleukin-2 MeSH
• interleukin-3 MeSH
• interleukin-4 MeSH
• interleukin-5 MeSH
• interleukin-6 MeSH
• messenger RNA MeSH

• MeSH
• interleukin-2 * MeSH
• lidé MeSH
• protinádorové látky * MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• interleukin-2 * MeSH
• protinádorové látky * MeSH

• MeSH
• aktivace lymfocytů MeSH
• experimentální sarkom chemicky indukované   imunologie   MeSH
• interleukin-1 farmakologie   MeSH
• interleukin-2 metabolismus   farmakologie   MeSH
• methylcholanthren MeSH
• myši inbrední C57BL MeSH
• myši MeSH
• receptory interleukinu-2 analýza   metabolismus   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• interleukin-1 MeSH
• interleukin-2 MeSH
• methylcholanthren MeSH
• receptory interleukinu-2 MeSH

The aim of this review is to evaluate the results of IL-2 therapy of cancer two decades after the first experiments and to discuss whether and which results of local, systemic and adjuvant IL-2 therapy in preclinical models can be translated into clinics. The attention is also focused on the development and utilization of the IL-2 gene-modified tumour vaccines for therapeutic purposes. The prospects and limitations of both, IL-2 therapy and IL-2 gene therapy are discussed.

• MeSH
• genetická terapie * MeSH
• interleukin-2 genetika   terapeutické užití   MeSH
• lidé MeSH
• nádory farmakoterapie   terapie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• interleukin-2 MeSH

The authors assessed, using the method of sandwich enzyme immunoassay (ELISA), the soluble receptor for interleukin-2 (s-r IL-2). In patients with rheumatoid arthritis mean values of 620.5 = 500.0 u./ml were recorded which was significantly higher than in patients with osteoarthritis (p less than 0.001) (313.3 +/- 155 n./ml) and in healthy controls (181.7 +/- 159.6 n./ml). In patients with rheumatoid arthritis a correlation was found between the activity of the disease expressed by means of Lansbury's index (r = 0.61, p less than 0.01). There was no correlation between s-r IL-2 and the sedimentation rate (r = 0.32, p = n. s.). The author reviews the literature and discusses the hypothesis that s-r IL-2 acts as a competitive inhibitor for interleukin-2.

• MeSH
• biologické markery krev   MeSH
• dospělí MeSH
• ELISA MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• osteoartróza krev   MeSH
• receptory interleukinu-2 krev   MeSH
• revmatoidní artritida krev   diagnóza   MeSH
• rozpustnost MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• biologické markery MeSH
• receptory interleukinu-2 MeSH

The present study was designed to compare the tumour inhibitory effects of local therapy based on insertion of cloned IL-2, IL-4, or IL-6 genes into the genome of murine plasmacytoma X63-Ag8.653, followed by injection of the genetically modified cells to the vicinity of the parental plasmacytoma growing in syngeneic mice. It was also designed to investigate the effects of combined gene therapy with IL-2- and IL-6-producing plasmacytoma cells. It has been found that insertion of the IL-2 gene into the genome of X63-Ag8.653 cells can abrogate tumorigenicity of the transduced cells more effectively than insertion of the IL-4 or IL-6 gene. Peritumoral administration of the genetically modified plasmacytoma cells producing IL-6 (X63-h-IL-6) resulted in a therapeutic effect comparable with that of the IL-2-producing cells (X63-m-IL-2), whereas no substantial therapeutic effect of IL-4-producing cells (X63-m-IL4) was observed. The combined gene therapy with IL-2- and IL-6-producing cells did not give any additive or potentiated therapeutic effect.

• MeSH
• cytotoxicita imunologická MeSH
• genetická terapie * MeSH
• interleukin-2 genetika   terapeutické užití   MeSH
• interleukin-4 genetika   terapeutické užití   MeSH
• interleukin-6 genetika   terapeutické užití   MeSH
• interleukiny genetika   terapeutické užití   MeSH
• myši inbrední BALB C MeSH
• myši MeSH
• nádorové buňky kultivované MeSH
• plazmocytom genetika   terapie   MeSH
• transfekce MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH
• Názvy látek
• interleukin-2 MeSH
• interleukin-4 MeSH
• interleukin-6 MeSH
• interleukiny MeSH